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Strengths and limitations of this study
 ► Robust consensus methods with international par-
ticipation will agree standardised measures for use 
in all future research and audit studies of implant- 
based breast reconstruction which will improve the 
quality and comparability of future results.
 ► Candidate measures for inclusion in the Delphi pro-
cess will be selected based on high- quality system-
atic reviews.
 ► This study will focus on generating consensus 
among healthcare professionals; robust patient and 
participant involvement will be needed to ensure 
that the patient- reported outcomes recommended 
in this study will be acceptable to patients undergo-
ing implant- based reconstruction.
 ► Further work will be needed to determine the degree 
to which the planned implementation of the core 
measurement set has been successful.
AbStrACt
Introduction Outcome reporting in research studies 
of breast reconstruction is inconsistent and lacks 
standardisation. The results of individual studies therefore 
cannot be meaningfully compared or combined limiting 
their value. A core outcome set (COS) has been developed 
to address these issues and identified 11 key outcomes 
to be measured and reported in all future research and 
audit studies in reconstructive breast surgery (RBS). A 
COS represents what key outcomes should be measured. 
The next step is to determine how and when this should 
be done. The aim of this study is to develop a core 
measurement set (CMS) for use in research and audit 
studies in implant- based breast reconstruction.
Methods and analysis The CMS will be developed in 
accordance with the guidance developed by the Core 
Outcome Measures in Effectiveness Trials initiative (COMET) 
and COnsensus- based Standards for the selection of health 
Measurement Instruments (COSMIN) group for the selection 
of outcome measurement instruments (OMIs) for relevant 
outcome domains included in the RBS COS. This will involve 
three phases with strategies to promote implementation 
as a final additional phase. The phases are (1) conceptual 
considerations in which the target population, procedures 
and settings are defined; (2) systematic reviews to identify 
existing clinical, patient- reported and cosmetic OMIs and, if 
appropriate, assess their quality using COSMIN methodology; 
(3) a modified Delphi process including sequential Delphi 
surveys involving approximately 100 healthcare professionals 
and a face to face consensus meeting to agree and ratify 
which outcome definitions and OMIs should be used and 
standardised time points for assessment; (4) strategies to 
promote dissemination and adoption of the CMS.
Ethics and dissemination Ethical approval has been 
granted by University of Bristol Faculty Research Ethics 
Committee FREC ID 60221. Dissemination strategies will 
include scientific meeting presentations and peer- reviewed 
journal publications. Implementation activities will include 
engagement with journal editors and funders to promote 
uptake and use of the CMS.
IntroduCtIon
Appropriate outcome selection is vital if 
research is to inform practice and guide 
policy. The development and use of core 
outcome sets (COSs), a scientifically agreed 
minimum set of outcomes that should be 
measured and reported in effectiveness 
studies in a given area is one way in which 
inconsistent and heterogeneous outcome 
selection may be addressed.1
A COS for reconstructive breast surgery 
(RBS) has recently been developed.2 This study 
used robust Delphi consensus methodology 
with over 300 patients and healthcare profes-
sionals followed by consensus meetings to agree 
and ratify an 11- item COS.2 The COS includes 
clinical (implant and flap- based complications, 
major complications and unplanned surgery), 
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patient- reported (quality of life, normality, emotional and 
physical well- being and self- esteem) and cosmetic (women’s 
cosmetic satisfaction) outcomes that all stakeholders felt 
were important to measure as a minimum in future effec-
tiveness studies in RBS.
While a COS is an important step in determining what 
outcomes should be measured in research and audit studies 
in RBS, it does not describe how these key outcomes should 
be measured. The next step in improving the quality and 
consistency of outcome reporting in RBS is therefore to 
develop a core measurement set (CMS), a set of instruments 
to assess the COS and to generate consensus regarding the 
standard time points at which these outcomes should be 
measured.3–5 The need for a CMS to improve the quality 
and value of research in oncoplastic and RBS was identi-
fied as a research priority in the recently published breast 
surgical gap analysis.6
The COS was developed for RBS as a whole but this 
includes a diverse range of procedures ranging from total 
breast reconstruction following mastectomy with implants 
or tissue- based procedures and oncoplastic breast conser-
vation using both volume replacement and displacement 
techniques. The COS therefore includes procedure- specific 
domains such as ‘implant- related complications’ and 
‘donor- site morbidity’ that would not be applicable to all 
types of reconstruction. Furthermore, the types of compli-
cations that are relevant for specific procedure types will 
differ. For a CMS to be meaningful and easily applicable in 
practice, a separate set of core measures for each procedure 
group will be needed. As implant- based breast reconstruc-
tion (IBBR) is the most commonly performed procedure 
worldwide7 8 and a rapidly evolving area of clinical practice 
with new procedures and techniques such as prepectoral 
reconstruction currently being introduced and evaluated,9 
development of a CMS for IBBR is a research priority. It is 
anticipated that CMS for autologous breast reconstruction 
and oncoplastic breast conservation will be developed in 
the future using similar methods.
Outcome assessment and reporting in IBBR will only be 
improved if the resultant CMS is accepted and adopted 
into practice.5 Studies to date have reported variable 
success in the implementation of COS in other areas.10–12 
Reasons for this are complex but optimising ‘buy in’, for 
example, by involving appropriate and geographically 
diverse stakeholder groups in the development process 
and using a solid dissemination strategy have been identi-
fied as important.10 Effective strategies to promote dissem-
ination and implementation will therefore be necessary 
to increase awareness of the CMS in the reconstructive 
community and promote its uptake and use in future 
research studies.5
Aim
The aim of the study is to develop a CMS for IBBR and 
develop strategies by which awareness of the CMS and 
its subsequent adoption and implementation may be 
enhanced.
MEthodS And AnAlySIS
overview
The development of the CMS will be based on the guid-
ance developed by Core Outcome Measures in Effective-
ness Trials (COMET) and COnsensus- based Standards 
for the selection of health Measurement Instruments 
(COSMIN) on the selection of outcome measurement 
instruments (OMIs) for the outcome domains included 
in the RBS COS.13 This involves three stages with strat-
egies to promote implementation as a final additional 
phase.
1. Conceptual considerations and scope of the CMS.
2. Systematic reviews to identify existing OMIs and assess 
their quality.
3. An international Delphi process to establish consensus 
among stakeholders regarding which complications, 
definitions and OMIs should be used and standardised 
time points for assessment and consensus meetings to 
agree and ratify these decisions.
4. Strategies to promote dissemination and adoption of 
the CMS.
Patient and public involvement
Patients and members of the public will be involved 
throughout the study. A patient and public involvement 
(PPI) group will be established as part of the project and 
a patient will be invited to sit on the study steering group. 
They will contribute to all study phases and dissemination 
of the results.
Phase 1. Conceptual considerations and scope of the CMS
The first step in CMS development is to agree the 
construct (ie, outcome or domain) to be measured and 
the target population.
The constructs were identified in the original COS 
study2 and include 11 domains, 9 of which are rele-
vant to IBBR. These comprise three clinical (major 
complications, unplanned surgery for any reason and 
implant- related complications) and six patient- reported 
(normality, quality of life, women’s cosmetic satisfac-
tion, physical well- being, emotional well- being and self- 
esteem) outcome domains. The two remaining core 
outcome domains, flap- related complications and donor- 
site morbidity are not relevant to IBBR so will not be 
included in this process.
The target population for the CMS will be adult women 
undergoing immediate or delayed breast reconstruction 
surgery using implants or expanders placed in any posi-
tion (subcutaneous or submuscular) with or without mesh 
following mastectomy for breast cancer or risk reduction.
The COS was developed for use in research and audit 
studies of RBS and the CMS will similarly be developed 
for use in any clinical evaluation of IBBR to optimise the 
value of this work and allow the results of all future studies 
to be compared and combined.
An expert steering group comprising breast and plastic 
surgeons, clinical nurse specialists and patients will be 
convened to oversee the study, review the results of the 
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systematic review, design the Delphi survey and act as 
champions for the adoption and dissemination of the 
CMS in the breast reconstruction community.
Phase 2. Identification of existing oMIs and oMI quality 
assessment using systematic reviews
The term ‘OMI’ will be used to refer to the method by 
which the outcome is being measured (the tool used to 
assess the outcome) and may be a single question, a ques-
tionnaire or other appropriate tool depending on the 
outcome to be assessed.3
Systematic reviews will be used to identify existing 
measurement instruments for each of the relevant IBBR 
core outcomes and to identify gaps where new instru-
ments may be needed. The review has been registered 
on the PROSPERO International prospective register of 
systematic reviews (CRD42017075211).
Clinical outcomes
The existing systematic review of the clinical outcomes 
of breast reconstruction14 will be updated to identify all 
additional published randomised clinical trials (RCTs) 
or RCT protocols and non- randomised comparative or 
non- comparative studies or published protocols reporting 
outcomes of or planning to recruit a minimum of 100 
patients undergoing IBBR following mastectomy using 
any technique. A minimum sample size of 100 patients was 
used in the original systematic review to restrict focus to 
studies that would be sufficiently large to influence prac-
tice. Ongoing clinical trials will be identified from  clinical-
trials. gov and primary and secondary outcome measures, 
outcome definitions and time point of outcome assess-
ments extracted.
Abstracts will be screened by one reviewer (SP) to iden-
tify eligible studies and outcome definitions and time 
point of outcome assessments will be extracted verbatim 
with checking of a proportion by a second reviewer (CD). 
The individual outcomes and definitions will be grouped 
according to core clinical outcome domain (implant- based 
complications, major complications, unplanned surgery for 
any reason) for use in phase 3, the Delphi survey.
Outcomes, definitions, time points for outcome assess-
ments and composition of outcome domains will be 
reviewed by the expert steering group for completeness 
and relevance prior to progression to the Delphi process.
Patient-reported outcomes
A structured search of MEDLINE, EMBASE and 
PsycINFO will identify systematic reviews of OMIs for rele-
vant patient- reported outcome domains (health- related 
quality of life (HRQL), emotional well- being,; physical 
well- being, normality, self- esteem, cosmetic satisfaction). 
If systematic reviews are of high quality and have under-
taken a quality assessment of the OMIs, then one OMI will 
be selected and presented to a group of key stakeholder 
representatives at the end of the process. If there are no 
systematic reviews or they are of poor quality, a new or 
updated systematic review of the measurement properties 
of patient- reported outcome measures (PROMs) devel-
oped for or validated in women undergoing RBS will be 
performed.15 16
A systematic search will be performed in MEDLINE 
and EMBASE using search terms relating to the construct 
of interest (PROMs) and the target population (IBBR) 
combined with the measurement properties filter 
described by Terwee et al.17 Primary studies reporting the 
development or validation of PROMs in women under-
going RBS will be eligible for inclusion with particular 
reference to studies evaluating instruments relevant to 
each of the core patient- reported outcomes (HRQL, 
normality, women’s cosmetic satisfaction, physical well- 
being, emotional well- being or self- esteem). Only full- 
text papers published in English will be included in the 
review. Eligibility assessments and data extraction will be 
performed by two reviewers (SP, CD) and discrepancies 
resolved by discussion with a third reviewer (KA). Tables 
will be constructed to summarise included study charac-
teristics, instrument characteristics, measurement prop-
erties and interpretability. The methodological quality of 
included studies will be assessed using the COSMIN check-
list.18 Best evidence synthesis will be undertaken if more 
than one study has assessed a particular measurement 
property. For each instrument identified in the review, 
recommendations will be made regarding its potential 
applicability to the CMS or the need for further valida-
tion work. The most appropriate instrument for each 
core outcome will be identified. If more than one instru-
ment is considered equally valid, details of each poten-
tial instrument will be included in the Delphi process to 
determine which tool should preferentially be used in the 
IBBR–CMS. If no suitable instrument is identified for any 
of the core outcomes, work will be undertaken with key 
stakeholders to develop and validate a new tool according 
to the guidelines reported in the COSMIN checklist.16
Cosmetic outcomes
The cosmetic outcomes identified in the COS are patient 
reported, so identification of appropriate measures will 
be addressed in the PROM systematic review.
Phase 3. delphi process to establish consensus regarding oMI 
section, definitions and time point
The Delphi process will consist of initial questionnaire 
development based on the results of the systematic 
reviews, sequential questionnaire administration and a 
final consensus meeting with the aim of generating stake-
holder agreement regarding the final CMS.
Questionnaire development
The complications, definitions and time points identified 
from the updated clinical systematic review and details 
relating to appropriate PROMs for example, number and 
content of items for each core outcome will be reviewed. 
Only complications reported in more than 10% of studies 
in the systematic review will be included in the Delphi 
together with the most commonly reported definitions and 
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outcome assessment time points. These will be operation-
alised and formatted into items for the Delphi survey which 
will be used to generate consensus for the IBBR CMS.19 20 
It is anticipated that the survey will have four sections to 
determine: (1) what complications should be included in 
the ‘implant- related complications’ domain; (2) the most 
appropriate standardised definitions of complications to be 
used in the final CMS; (3) the most appropriate validated 
PROM (if any) for measuring each of the patient- reported 
outcome domains and (4) the most appropriate time point 
for short- term and long- term clinical and patient- reported 
outcome assessment in future clinical studies.
The items for section (1) to be included in the implant- 
related complication domain, will be rated on a 9- point 
Likert scale from 1 (not important) to 9 (essential) based 
on the Grading of Recommendations Assessment, Devel-
opment and Evaluation scale for scoring the importance 
of including the item in a COS as per established method-
ology.21 For section (2) selection of the most appropriate 
outcome definitions and section (4) selection of the 
most appropriate time points for outcome assessment, 
the most commonly reported definitions and time points 
identified from the systematic reviews will be presented 
and respondents asked to select the most appropriate 
definition or time point for each outcome. Finally for 
section (3) details of any validated PROM identified for 
each patient- reported outcome (PRO) domain will be 
presented and respondents asked if (1) the PROM is 
appropriate and (2) if more than one validated PROM is 
available, to rank the instruments from best (most appro-
priate) to worst (least appropriate).
The structure and content of the Delphi survey will be 
reviewed and discussed by the members of the steering 
group to ensure that the candidate complications, defini-
tions and time points are complete, relevant and practical 
prior to the piloting phase.
The questionnaire will be piloted with a group of breast 
and plastic surgeons to test understandability and accept-
ability prior to its use in Delphi round 1.
Selection and recruitment of study participants
Key stakeholders including surgeons performing IBBR and 
specialist nurses involved in counselling patients under-
going IBBR will be invited to complete the Delphi survey.
Patients will not be involved in the Delphi process as 
they do not have the technical knowledge to select the 
most appropriate complications or definitions for use in 
the CMS. Patients, however, will be involved in the steering 
group and results of the Delphi process, in particular the 
PROMs and proposed time points for outcome assess-
ment, will be discussed with a PPI focus group to ensure 
that they are acceptable and meaningful to patients.
Multi- national professional stakeholders will be invited 
to participate via the professional associations including 
the UK Association of Breast Surgery and British Associa-
tion of Plastic Reconstructive and Aesthetic Surgeons; and 
international collaborative groups including the Onco-
plastic Breast Consortium, personal research networks and 
social media. Invitations will include a link to an electronic 
survey.22 The first page of the survey will include an invita-
tion letter explaining the background and purpose of the 
study. The Delphi process will be explained and the impor-
tance of participating in each round emphasised.
Delphi survey rounds
Participants will complete up to three sequential rounds 
of the Delphi survey over a 3- month period. In each 
round, participants will be asked to score the importance 
of including each identified complication in the implant- 
related complications domain and select the most appro-
priate outcome definitions, PROMs and time points for 
outcome assessment. All surveys will be administered online 
using the secure REDCap electronic data capture software.22
Participants who complete round 1 will be sent the round 
2 survey. The second survey will contain all items retained 
from round 1 (see Data analysis section) with anonymised 
feedback from the previous round in the form of summary 
scores (eg, median scores for complications, proportions 
of participants selecting each definition/PROM/time 
point). Graphical representations will be used if appro-
priate to aid data visualisation. Participants will be asked to 
rescore each item based on the feedback received. If there 
is insufficient consensus after round 2, a further round may 
be conducted. This will be methodologically identical to 
round 2. Items retained after the final Delphi round will be 
carried forward to the consensus meeting.
Consensus meetings
A purposive sample of professionals who participated in 
the Delphi survey will be invited to attend a face to face 
consensus meeting to discuss and agree the final CMS.
A summary of the survey results will be presented. 
Participants will be asked to ratify inclusion/exclusion 
of complications/measures during the Delphi survey 
and anonymously revote on complications/measures 
for which consensus was not reached during the Delphi 
or for which there were disagreements (see Data anal-
ysis section). Moderated discussion and revoting will be 
undertaken as necessary until consensus is achieved.
PPI focus groups will be held with patients to discuss 
OMI selection based on content, response burden and 
time point of PROMs assessment.
Sample size
There is no standardised methodology for sample size calcu-
lation in CMS development but as with COSs,23 the aim is to 
obtain good representation from key stakeholder groups. 
IBBR in the UK is predominantly performed by breast 
surgeons with plastic surgeons performing fewer proce-
dures. Internationally, RBS is also performed by surgical 
oncologists and gynaecologists. A pragmatic approach24 
will therefore be taken to ensure adequate representation 
of surgeons performing the technique. It is anticipated 
that approximately 100 professionals will be recruited to 
the study. The majority of the Delphi items refer to tech-
nical surgical issues so it is not considered appropriate to 
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Table 1 Definitions of consensus and management of items between rounds
Category Definition Action
Items for inclusion in ‘implant- related complication’ domain
  Consensus in Scored as very important (7–9) by ≥70% and not 
important (1–3) by <15% of respondents
Item retained for next survey round/consensus meeting
  Consensus out Scored as not important (1–3) by ≥70% and very 
important (7–9) by <15% of respondents
Item discarded after round 2 (to be ratified at consensus 
meeting).
  No consensus Criteria above not met Item retained for next survey round/consensus meeting
Selection of outcome definitions
  Consensus in Definition selected by ≥75% respondents Definition retained for next survey round/consensus meeting
  Consensus out Definition selected by <5% respondents Definition dropped after round 2
  No consensus Criteria above not met Definition retained for next survey round/consensus meeting
Selection of patient- reported outcome measures
  Consensus in Scored as ‘best’ by ≥75% and ‘worst’ by <15% of 
respondents
PROM retained for next survey round/consensus meeting
  No consensus Criteria above not met PROM retained for next survey round/consensus meeting
Selection of time point of outcome assessment
  Consensus in Time point selected by ≥75% respondents Time point retained for next survey round/consensus meeting
  Consensus out Time point selected by <5% respondents Time point dropped after round 2
  No consensus Criteria above not met Time point retained for next survey round/consensus meeting
involve patients in this process. A separate PPI group will 
be convened at which candidate PROMs and proposed 
time point of assessment will be presented and discussed 
to ensure these are appropriate and important to patients.
Data analysis
Retaining or dropping items between survey rounds
Data will be collected using REDCap,22 a mature, secure 
web application for building and managing online 
surveys and databases hosted at Bristol Medical School 
https:// sscmredcap. bris. ac. uk/ redcap/ and analysed 
using STATA 14 MP ( www. stata. com).
Descriptive statistics will be used to summarise the 
result from round 1 including the summary scores for 
each complication (eg, median, range) and the propor-
tion of participants rating each complication as very 
important (score 7–9), equivocal (scores 6–4) or not 
important (scores 1–3). The percentage of respondents 
selecting each candidate definition and time point 
of outcome assessment will be calculated. For ranked 
items (PROMs), the percentage of respondents rating 
each item best and worst will be recorded. All items will 
be retained between rounds 1 and 2. After round 2, 
items will be categorised as described in table 1. A third 
round will be held if the number of items for which no 
consensus is achieved following round 2 is too large for 
discussion at the consensus meeting (eg. >30). Round 3 
will be analysed using the same criteria as described in 
table 1.
Complications/definitions/PROMs/time points for 
which there is disagreement by predetermined criteria 
(table 1) will be carried forward for discussion and voting 
at the consensus meeting.
Consensus meeting
Following the first round of voting, items will be catego-
rised as ‘consensus in’, ‘consensus out’ or ‘no consensus’ 
as per table 1. Items voted ‘consensus in’ will be included 
in the CMS; items voted ‘consensus out’ will be discarded 
and items for which there is ‘no consensus’ will be redis-
cussed. Further rounds of voting and discussion will take 
place until consensus is achieved. The consensus meeting 
will conclude with participants ratifying the final CMS.
Phase 4. Strategies to promote awareness, uptake and 
adoption of the CMS
The implementation phase will use a range of methods to 
raise awareness of the CMS and promote its adoption as 
recommended by the COMET initiative group.1 This will 
include publication of the CMS and consensus statement 
in a leading journal; presentation at breast and plastic 
surgical meetings; dissemination to journal editors, profes-
sional associations, clinical guideline developers, Cochrane 
reviewers and funders requesting that all future studies, 
reviews, publications or applications in IBBR include the 
CMS.1 Guidance material will be prepared and made freely 
available to aid researchers in adoption of the CMS. Use 
of the CMS will be monitored at reviewed 5 years following 
the publication to evaluate the degree to which these imple-
mentation strategies have been successful.5
EthICS And dISSEMInAtIon
Dissemination strategies will include scientific meeting 
presentations, peer- reviewed journal publications and 
plain English summaries for patient and public dissemi-
nation. Social media will also be used to raise awareness of 
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the CMS in the wider international reconstructive commu-
nity. Implementation activities will include engagement 
with journal editors and funders to promote uptake and 
use of the CMS and patient groups and charities to raise 
awareness of the CMS and its importance.
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